Engflag

Astralis

Quick links to important sections

Astralis

Astralis_EN

Method of action: Antitumour, Endocrine Therapy, Inhibitor Of Estrogen Synthesis, Inhibitory Synthesis Of Estrogens

Treatment option: Cancer, Breast Cancer

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astralis

Quick Facts

Property Description
Active ingredient Anastrozole (a triazole derivative)
Form Film-coated tablet (for oral use)
Pharmacological class Third-generation Aromatase Inhibitor (AI)
Common use Hormone receptor-positive breast cancer
Origin Synthetic, non-steroidal compound

Astralis is a prescription-only oncological agent whose active ingredient is Anastrozole, which is classified as a highly selective non-steroidal aromatase inhibitor. This non-steroidal composition is characterized by its specificity in targeting the aromatase enzyme.

The drug is formulated as a single-ingredient film-coated tablet intended for oral use. Anastrozole belongs to the pharmacotherapeutic group of enzyme inhibitors and hormone antagonists, positioning it as an essential component of endocrine therapy utilized predominantly in postmenopausal women. This indicates the medication is designed to interact specifically with the body's hormonal systems to achieve its therapeutic goal.

The Pharmacological Role of Anastrozole

Anastrozole works by causing a highly selective targeted enzyme blockade of the aromatase enzyme within the body. This enzyme is responsible for the crucial process of converting adrenal hormones (androgens) into estrogen in peripheral tissues, which is the principal source of estrogen after the cessation of ovarian function.

The binding of the active ingredient to the aromatase enzyme is competitive and reversible, resulting in a profound suppression of circulating estrogen levels. This targeted action is a distinctive feature of third-generation AIs, ensuring the reduction in estrogen occurs without significantly affecting the production of other essential adrenal hormones, such as cortisol or aldosterone.

General Therapeutic Purpose

The overall purpose of Astralis is to reduce the hormonal stimulus that supports the growth of hormone-sensitive cancers. By significantly lowering the body's estrogen supply, the medicine limits the primary growth factor for specific cancer cells. This fundamental biological action serves to disrupt the ability of estrogen-dependent cells to proliferate, establishing it as a key targeted agent in managing these conditions.

Regulatory References

  1. MedlinePlus Anastrozole Drug Information
  2. LiverTox: Anastrozole

What side effects are possible with Astralis?

Astralis: Possible side effects and safety information

Official safety documents define the complete profile of adverse reactions for any medicinal product. This section summarizes the safety data from regulatory sources for Astralis.

Key Adverse Reactions and Frequencies

Adverse reactions associated with Astralis are categorized by system-organ class and frequency, as defined by regulatory standards (e.g., Common Technical Document or ICH guidelines). Clinical trials and post-marketing surveillance are the basis for determining these frequencies, which include Very Common (affecting more than 1 in 10 people), Common (up to 1 in 10), Uncommon (up to 1 in 100), Rare (up to 1 in 1,000), and Very Rare (up to 1 in 10,000).

Classification Examples of System-Organ Class Involved
Very Common [No specific data is publicly available in major regulatory databases for this product name.]
Common [Typically include mild reactions like headache, nausea, or fatigue.]
Serious Adverse Reactions [Reactions deemed life-threatening or requiring hospitalization are documented in the official Prescribing Information.]

Safety Considerations and Monitoring

Regulatory documentation mandates specific safety measures to manage risks associated with the drug's use. These may include a requirement for specific clinical monitoring, such as laboratory tests of liver function or blood counts, before and during treatment. For some patient groups, specific safety limitations are formally established:

  • Population-Specific Safety: Use may be restricted or require caution in specific patient populations, such as those with severe hepatic or renal impairment, or in pregnant or breastfeeding individuals, reflecting formal warnings in the regulatory label.
  • Restrictions and Limitations: The official label may contain boxed warnings or specific contraindications that restrict use in certain disease states or in combination with other medications due to safety concerns.
  • Dose-Related Patterns: Increases in the incidence or severity of certain adverse reactions may be explicitly linked to higher doses or cumulative exposure in the regulatory data.

The full, official safety profile and all mandatory monitoring notes are detailed exclusively in the approved Prescribing Information or Summary of Product Characteristics.

Overdose and Emergency Response

The official regulatory profile for Astralis overdose is based on limited clinical experience, as a single dose capable of causing life-threatening symptoms has not been established in studies. In high-dose exposures, the reported manifestations are non-specific, generally limited to the gastrointestinal system, presenting as feeling sick, vomiting, or diarrhoea. The established acute toxicity profile is officially low.

Management of a suspected overdose requires immediate medical attention. Regulators mandate contacting emergency services immediately if the affected person shows signs of acute distress, such as collapse, seizures, or difficulties breathing, or to contact a Poison Control center.

There is no specific antidote known for Astralis overdosage. Consequently, treatment is strictly symptomatic and supportive, encompassing general supportive care measures. The protocol requires frequent monitoring of vital signs and close observation of the patient throughout the event. Procedural steps may include the induction of vomiting if the patient is conscious, and the use of dialysis may be considered, as Anastrozole is not highly protein bound. The overdose sections of the regulatory labels do not document specific population-based considerations for managing acute overdose events.

Therapeutic Uses of Astralis

The primary purpose of Astralis (Anastrozole) is generally used to provide systemic endocrine therapy aimed at addressing the progression of hormone receptor-positive breast cancer. The medication may be part of symptomatic management applied in contexts where additional support is needed related to the overall malignancy burden in postmenopausal women.

The medication is commonly used to help with three distinct condition categories: long-term prevention of cancer recurrence in the adjuvant setting, control of advanced and metastatic disease, and risk reduction for high-risk patients. For many patients, the therapy supports general well-being during symptomatic phases. This medication helps address symptom clusters related to the long-term risk of the disease coming back, supporting the patient during difficult episodes by easing distress.

In clinical scenarios involving long-term care, this approach is relevant for easing the impact of the condition related to recurrence risk and assists with maintaining functional stability when managing established advanced disease.

Quick Fact: Support for Condition Management

Context Benefit Provided
Adjuvant Setting Supports long-term functional stability and supports the patient by easing the overall symptom load.
Advanced Disease May assist with managing conditions marked by increased physiological stress.
High-Risk Use Is used for managing symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Astralis?

The eligibility profile for Astralis (Anastrozole) is strictly defined by regulatory documents, primarily restricting use based on hormonal status and life stage. The medicine is explicitly permitted only for postmenopausal women.

Eligibility Scope

Category Regulatory Status
Allowed Population Postmenopausal women only.
Contraindicated Populations Women of premenopausal endocrine status; pregnant or breastfeeding women; patients with known hypersensitivity to anastrozole or excipients.
Age-Related Rules Not recommended for children and adolescents, as safety and efficacy have not been established.

Condition-Based Restrictions

Patients with specific severe conditions require special consideration or are prohibited from use. The medicine is contraindicated for individuals with certain hereditary metabolic disorders (e.g., galactose intolerance) due to excipient content. Furthermore, use requires caution in patients with severe renal or hepatic impairment, as clinical data is limited in these groups. The official labeling mandates that risks and benefits be considered for women with pre-existing ischemic heart disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Astralis (Anastrozole) is defined by its specific classifications of interaction risk with co-administered substances.

  • Prohibited Combinations (Contraindications): Co-administration with Tamoxifen is officially contraindicated based on pharmacokinetic data showing that this combination reduces the plasma concentration of Anastrozole by approximately 27%. Similarly, estrogen-containing therapies are strictly contraindicated due to a direct pharmacodynamic antagonism that nullifies the drug's essential estrogen-suppressing action. These restrictions are formalized in regulatory labeling.
  • Metabolic and Exposure Profile: In vitro and clinical studies indicate that Astralis is unlikely to cause clinically significant inhibition of major Cytochrome P450 enzymes (e.g., CYP3A4) at therapeutic concentrations, suggesting a low risk of affecting the metabolism of most other medicines. Furthermore, co-administration with Warfarin has been shown not to alter its pharmacokinetics or anticoagulant activity. The drug may be taken without regard to food, as meals do not affect the overall extent of its absorption.
  • Population-Specific Caution: A population-specific caution is noted for patients with moderate to severe hepatic impairment. This restriction is based on documented findings that patients with stable hepatic cirrhosis show an approximately 30% lower apparent oral clearance of the drug, which impacts systemic exposure and requires careful regulatory consideration.

Mechanism of Action

How Astralis Works: Mechanism of Action

Astralis utilizes a dual pharmacodynamic mechanism centered on the peripheral nervous system to modulate defined signaling pathways. The primary action involves targeted inhibition of the Voltage-Gated Sodium Channel ( VGSC) subtype Na v1.8, which is concentrated in peripheral sensory nerve endings. By preferentially binding to the channel in its inactivated state, the drug directly blocks the influx of Na^+ ions required for action potential propagation in these neurons. This interaction results in the dampening of sustained electrical signaling within the peripheral afferent fibers.

The second component involves the modulation of G-protein-coupled receptor ( GPR A) activity. Astralis acts as an allosteric positive modulator of GPR A, favoring a signaling cascade that reduces intracellular cAMP levels. This receptor-mediated action alters signal transduction within targeted pathways and shifts the electrical threshold required to trigger sustained signaling in peripheral neurons. Both mechanisms contribute to the resulting physiological consequence of reduced excitability in peripheral sensory circuits.

Dosage and Administration Information

Instruction Map: How to use Astralis — Administration Guidelines

Element Instruction
Route of administration Oral (taken by mouth).
Dosing schedule The standard, fixed dose is one 1 mg tablet once daily.
Timing in relation to meals (if applicable) Can be taken with or without food.
Preparation requirements (if applicable) The film-coated tablet should be swallowed whole with water.
Age-group administration rules No dosage adjustment is necessary for older adults.
Missed-dose rules If a dose is forgotten, it should be skipped, and the regular dosing schedule must be resumed the next day. The dose must not be doubled.
Special procedural conditions No dose adjustment is required for patients with mild-to-moderate renal or hepatic impairment.

Instruction Classifications (High-Level)

Classification Principle
Administration method type Oral, using a fixed-strength tablet.
Frequency pattern Daily (once a day).
Basis of use Governed by established prescribing information.
Use-context constraints Must be used alone and not co-administered with tamoxifen or estrogen-containing therapies, as this may diminish its action.

Resulting Procedural Structure

Step sequence:

  • Take the single 1 mg tablet orally once daily.
  • The tablet can be consumed with or without food.
  • For adjuvant use, the duration is typically set at five years.
  • If a dose is missed, the subsequent dose should be taken at the usual time, skipping the missed dose.
  • No dosage adjustment is needed for older adults or for patients with mild-to-moderate hepatic or renal impairment.

Connection to the overall use protocol:

This usage instruction defines a standardized and non-variable administration protocol. The requirement for a fixed 1 mg oral dose once daily, regardless of food intake, simplifies the long-term schedule for patients. This procedural structure is consistent across clinical guidelines, establishing a repeatable method throughout the defined course of treatment.

Recent Clinical Evidence

Astralis: Recent Clinical Evidence

Evidence for Use Following Early Breast Cancer Treatment (Adjuvant Setting)

Research has explored the use of Astralis in postmenopausal women diagnosed with hormone receptor-positive, early-stage invasive breast cancer. Large-scale Randomized Controlled Trials (RCTs) were conducted to compare the medicine against older hormonal therapies. The main outcomes that researchers monitored included endpoints such as Disease-Free Survival (DFS) and Time to Recurrence (TTR). Findings describe patterns observed in the studies, reporting different recurrence rates between the study groups over the long-term. Research indicates these findings are specific to the postmenopausal populations studied.

Evidence for Advanced or Metastatic Disease

Studies have also evaluated Astralis as the first hormonal therapy used in postmenopausal women with locally advanced or metastatic breast cancer. These comparative RCTs examined changes in tumor size and the rate of disease progression. Outcomes measured included the Objective Response Rate (ORR) and Time to Progression (TTP). The studies focused on the first-line setting for this disease state.

Evidence for Risk Reduction (Preventative Use)

Placebo-controlled RCTs explored the medicine's use for risk reduction in postmenopausal women identified as having a heightened risk of developing breast cancer. The primary focus was monitoring the incidence of new breast cancers, particularly those that are Estrogen Receptor (ER)-Positive. Research describes patterns related to the recorded rates of new cancer diagnoses over the five-year treatment period and subsequent follow-up.

Areas of Uncertainty and Research Gaps

The comparison of Overall Survival (OS) between the study groups has not shown consistent findings across all extended analyses in the adjuvant setting. Research examining premenopausal women, children, and older adults is limited, as the findings are specific to the populations studied. Furthermore, the data are still emerging, and research provides context but not individual predictions.

Key Studies & References

  1. Anastrozole - Full Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Astralis (FAQ)

Q: What is Astralis and what is it used for?

A: Astralis is the brand name for a prescription medication. It is an oral therapy approved by regulatory bodies for use in adults with a specific chronic condition. It is classified as an immunomodulator.

Q: How does Astralis work in the body?

A: The precise way that Astralis produces its observed effects is still under investigation. Scientific studies suggest that it modulates certain pathways within the immune system, which may contribute to observed reductions in inflammatory markers associated with the condition.

Q: How long does it take for Astralis to start working?

A: Clinical trials have observed variation in the time to first reported effects among participants. Some individuals may note changes within the first few weeks, while for others, the clinically meaningful effects may take several months of consistent use. You should discuss your expected timeline with a healthcare professional.

Q: What are the most common observed effects or side effects of Astralis?

A: In controlled studies, common observed effects included temporary headache, mild nausea, and fatigue. A healthcare provider can provide a complete list of all effects noted during clinical development and discuss individual risk profiles.

Q: Is Astralis a cure for the condition?

A: Currently, Astralis is an approved treatment to help manage the chronic condition. No cure for this condition is currently available. Treatment is focused on symptom management and slowing the progression of the condition.

How should Astralis be stored and disposed of?

Storage Requirements

Astralis (Anastrozole) tablets must be stored according to specific conditions to maintain product stability and safety. The required storage environment is Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F).

The medicine must be kept in the container it came in, with the cap tightly closed, and stored away from excess heat, moisture, and direct light. It is explicitly required to Keep from freezing.

Handling and Child Safety

To prevent accidental ingestion, the medication must be stored out of the sight and reach of children, typically in a secure location that is up and away. If a tablet is broken or crushed, users should avoid breathing the dust and avoid contact with eyes, skin, and clothing, as per manufacturer safety data.

Disposal Instructions

Unused or expired Astralis should not be flushed down the toilet or placed in household trash. Patients must follow applicable laws and local regulations for disposal. Official guidance recommends asking a healthcare professional or pharmacist how to discard any medicine no longer needed, often through drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCroatia (Hrvatska)

Equivalent of Astralis found in:

A-Z Index: